[Evaluation of multidisciplinary treatment involving chemotherapy with cis-diamminedichloroplatinum, bleomycin (peplomycin) and 5-fluorouracil for advanced esophageal carcinoma].

Nihon Gan Chiryo Gakkai shi Pub Date : 1990-05-20
J Nakamura, H Nasu, O Masamune, Y Inoue
{"title":"[Evaluation of multidisciplinary treatment involving chemotherapy with cis-diamminedichloroplatinum, bleomycin (peplomycin) and 5-fluorouracil for advanced esophageal carcinoma].","authors":"J Nakamura,&nbsp;H Nasu,&nbsp;O Masamune,&nbsp;Y Inoue","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Twelve patients with unresectable squamous cell carcinoma of the esophagus were treated with a combination chemotherapy regimen consisting of cis-diamminedichloroplatinum (CDDP), bleomycin (BLM) or peplomycin (PEP), and 5-fluorouracil (5-FU). Ten of them received radiation therapy additionally. CDDP was administered once every 4 weeks at a dose of 50 mg/m2. Methylprednisolone of 250 mg was given intravenously 4 times at the same day with infusion of CDDP. BLM or PEP was administered intravenously at a dose of 20 mg/m2 every 2 weeks and 5-FU was administered at a dose of 330 mg/m2 on days 1-5, 15-19, and afterwards every 4 weeks. All patients received at least two courses of chemotherapy. All of them were evaluable. Complete and partial responses were obtained in one and eight cases, respectively. Responsive rate was 75.0%. The median duration of response was 17.0 weeks. The median duration of survival was 44.0 weeks in all patients, 46.1 weeks in responders and 17.9 weeks in non-responders. Nausea, vomiting, leucopenia, fever, nephrotoxicity and radiation esophagitis were observed as side effects but most of them were mild and well tolerated. In conclusion, this regimen was considered to be very useful as the chemotherapy for primary esophageal carcinoma.</p>","PeriodicalId":76232,"journal":{"name":"Nihon Gan Chiryo Gakkai shi","volume":"25 5","pages":"939-45"},"PeriodicalIF":0.0000,"publicationDate":"1990-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nihon Gan Chiryo Gakkai shi","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Twelve patients with unresectable squamous cell carcinoma of the esophagus were treated with a combination chemotherapy regimen consisting of cis-diamminedichloroplatinum (CDDP), bleomycin (BLM) or peplomycin (PEP), and 5-fluorouracil (5-FU). Ten of them received radiation therapy additionally. CDDP was administered once every 4 weeks at a dose of 50 mg/m2. Methylprednisolone of 250 mg was given intravenously 4 times at the same day with infusion of CDDP. BLM or PEP was administered intravenously at a dose of 20 mg/m2 every 2 weeks and 5-FU was administered at a dose of 330 mg/m2 on days 1-5, 15-19, and afterwards every 4 weeks. All patients received at least two courses of chemotherapy. All of them were evaluable. Complete and partial responses were obtained in one and eight cases, respectively. Responsive rate was 75.0%. The median duration of response was 17.0 weeks. The median duration of survival was 44.0 weeks in all patients, 46.1 weeks in responders and 17.9 weeks in non-responders. Nausea, vomiting, leucopenia, fever, nephrotoxicity and radiation esophagitis were observed as side effects but most of them were mild and well tolerated. In conclusion, this regimen was considered to be very useful as the chemotherapy for primary esophageal carcinoma.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[顺式二胺二氯铂、博来霉素(培霉素)、5-氟尿嘧啶联合化疗治疗晚期食管癌的疗效评价]。
12例不可切除的食管鳞状细胞癌患者采用顺式二胺二氯铂(CDDP)、博来霉素(BLM)或培霉素(PEP)和5-氟尿嘧啶(5-FU)联合化疗方案治疗。其中10人还接受了放射治疗。CDDP每4周给药1次,剂量为50mg /m2。甲基强的松龙250 mg,当日静脉滴注CDDP 4次。BLM或PEP每2周静脉给药20mg /m2, 5-FU在第1-5天、第15-19天、之后每4周静脉给药330mg /m2。所有患者均接受了至少两个疗程的化疗。它们都是可评估的。完全缓解和部分缓解分别为1例和8例。应答率为75.0%。中位反应持续时间为17.0周。所有患者的中位生存期为44.0周,有反应者为46.1周,无反应者为17.9周。不良反应有恶心、呕吐、白细胞减少、发热、肾毒性、放射性食管炎等,但多为轻微且耐受性良好。综上所述,该方案作为原发性食管癌的化疗方案是非常有效的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
[Chemoembolization therapy with lipiodol, cisplatin and etoposide for hepatocellular carcinoma]. [Relationship between human papillomavirus and oncogenes (c-myc, N-myc) amplification in human cervical cancers]. [Treatment of liver metastatic ovarian cancer with sequential administration of OK-432 and etoposide]. Flow cytometric analysis of nuclear DNA content in patients with recurrent epithelial ovarian cancer. [The effect on prognosis and the adverse drug reaction of intermittent cisplatin therapy in advanced ovarian cancer patients].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1